Background and Role at What Doctors Don’t Tell You (WDDTY)
Bryan Hubbard co‑founded What Doctors Don’t Tell You (WDDTY), a UK magazine and website focused on health and medicine, with author Lynne McTaggart, and he serves in an editorial leadership capacity.[1] WDDTY presents consumer‑facing content on prevention, treatment choices, and critiques of conventional care, positioning itself as a platform for alternative and integrative health perspectives.[1] The publication originated as a newsletter and later expanded into a print magazine and digital outlet with an international readership.[1]
Editorial Focus and Reception
WDDTY’s editorial stance emphasizes critical reporting on mainstream medicine alongside coverage of complementary and alternative approaches, which has drawn both interest from readers and scrutiny from medical commentators.[1] UK regulators and science writers have periodically criticized or challenged claims associated with the publication, reflecting an ongoing debate over standards of evidence in consumer health media.[1] As a co‑founder and editor, Hubbard’s public profile is closely tied to this outlet’s content and the reception it receives in the broader health discourse.[1]
Public Footprint and Notability
Hubbard’s notability primarily stems from his role in shaping WDDTY’s editorial output and brand, which has appeared on newsstands and engaged audiences interested in non‑conventional health narratives.[1] Discussions around WDDTY’s content—ranging from advocacy by supporters to criticism by skeptics—have contributed to ongoing public debate about the communication of medical evidence to lay audiences.[1]
Ibogaine: Context for Readers of This Wiki
Because this wiki focuses on ibogaine, the following provides concise, sourced context on the therapy for orientation; these statements do not imply authorship or endorsement by Bryan Hubbard.[2] Ibogaine is a psychoactive alkaloid from Tabernanthe iboga that has been investigated for substance use disorders, particularly opioids, with most data from observational studies and small trials outside the U.S.[2][3] Historical and legislative overviews note early 20th‑century isolation, later reports of anti‑addictive effects, and subsequent research pauses related to safety and scheduling. Readers can explore fundamentals at What Is Ibogaine? and How Ibogaine Works.[2]
Mechanistically, ibogaine and its metabolite noribogaine act across multiple targets—NMDA receptors, serotonin receptors, sigma sites, and ion channels—supporting hypotheses about craving reduction and neuroadaptation while also contributing to safety liabilities such as QTc prolongation via hERG channel effects.[2] Clinical evidence remains limited by a lack of large randomized trials, though small studies and cohorts report withdrawal suppression and periods of reduced use or abstinence; see syntheses for details and caveats.[3][4] For applied overviews, see Ibogaine Treatment: Evidence, Risks, Protocols & Legality and Ibogaine Clinics: Safety, Legality, Costs & Evidence.[2]
Safety and Risk Overview (Ibogaine)
Cardiac risk—particularly QTc prolongation and torsades de pointes—represents the principal safety concern with ibogaine, underscoring the need for medical screening, ECG monitoring, and avoidance of interacting substances.[5] Reviews and safety analyses recommend stringent protocols and highlight reports of serious adverse events in unregulated settings, reinforcing that self‑administration is unsafe.[5][2] Readers seeking practical guidance can review Ibogaine Side Effects: Risks & Safety and How to Get Ibogaine Treatment Safely for risk‑mitigation checklists.[5][2]
Legal Status and Access (Ibogaine)
Ibogaine remains a Schedule I substance in the United States, without FDA approval, though research exemptions apply in limited contexts; international policies vary from prescription frameworks to outright bans.[4] Policy analyses and guides note active reform discussions in certain jurisdictions and growing interest in safer analogs like 18‑MC, which has entered early‑phase human testing.[4] For country‑level detail and clinic considerations, see Ibogaine Legality by Country (2026 Guide) and Ibogaine Treatment Centers: Safety, Legality & Choosing One.[4][2]
Interpreting Health Claims in Alternative Medicine
The debate around alternative‑medicine reporting—including outlets like WDDTY—often turns on the strength of evidence, from mechanistic plausibility to controlled clinical outcomes.[1] In ibogaine’s case, promising observational data must be weighed against safety liabilities and the current absence of large randomized controlled trials, a balance emphasized in research summaries and safety reviews.[3][5] Readers comparing modalities can consult evidence‑focused pages such as Ibogaine for Opioid Addiction and Ibogaine vs. Ayahuasca to situate anecdotal claims within the peer‑reviewed literature and regulatory landscape.[2][4]